Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discount double whammy could cost €2.6bn: industry needs voice on German price body

This article was originally published in Scrip

Executive Summary

Increased mandatory discounts have this year hit pharmaceutical companies twice as hard as expected. In the first half of 2011 alone, the German government saved what it intended to save through the discounts over a 12 month period, says Dr Alexander Natz, Brussels representative for the BPI, the German association of mid-sized pharmaceutical companies. Dr Natz also believes that the German reimbursement body, the G-BA, needs a voice from the pharmaceutical industry if it is to reflect thinking across the spectrum of healthcare.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts